NCCN 2012 Congress Series: Gastrointestinal Cancers™

Durham, NC US
November 7, 2012

This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Gastrointestinal Cancers. Participants will learn how to implement the NCCN Guidelines recommendations into their practice and gain a clear understanding of the most up-to-date treatment recommendations for these cancers. As research continues in these areas and new information emerges, it is critical that clinicians are kept up-to-date and informed. This congress will communicate the NCCN Guidelines in a direct and interactive way to community oncologists and other clinical professionals.

There is a $49 fee for this educational activity for non-industry registrants.
An industry registrant is defined as anyone currently employed by a pharmaceutical or biotechnology company. 

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this educational activity, learners will be able to:

COLORECTAL CANCER

  • Describe the current management strategies for locoregional rectal cancer, including the role of pre- and postoperative radiation in combination with chemotherapy
  • State the selection criteria used to choose optimal therapy for patients with various stages of localized rectal cancer
  • Discuss the role of adjuvant therapy for stage II colon cancer
  • List the factors that identify patients with stage II colon cancer who may benefit from adjuvant therapy
  • Describe the recent studies that compare the efficacies of the various adjuvant treatments
  • Discuss the toxicity profiles of available chemotherapy regimens
  • List the factors that should be evaluated (including presentation, comorbidities, and molecular test results) prior to selection of therapy for advanced or metastatic colorectal cancer
  • Describe the types of chemotherapy regimens available for advanced or metastatic colorectal cancer and their associated toxicities

HEPATOCELLULAR CARCINOMA (HCC)

  • Identify the characteristics of patients at high-risk for developing HCC and the appropriate tests used to screen these high-risk individuals for HCC
  • Describe the surgical options and the criteria used for the selection of patients for hepatic resection and liver transplant
  • Discuss the clinical data supporting the use of targeted therapy and identify the characteristics of patients eligible for treatment with targeted therapies
  • Explain the roles of adjuvant and neoadjuvant therapy in local pancreatic cancer
  • Describe risk factors and genes involved in pancreatic cancer predisposition
  • Explain the general principles of chemotherapy for advanced and metastatic pancreatic cancer
  • Provide the rationale for multidisciplinary management of symptoms and describe palliative interventions that are unique to advanced pancreatic cancer

PANCREATIC CANCER

  • Explain the roles of adjuvant and neoadjuvant therapy in local pancreatic cancer
  • Describe risk factors and genes involved in pancreatic cancer predisposition
  • Explain the general principles of chemotherapy for advanced and metastatic pancreatic cancer
  • Provide the rationale for multidisciplinary management of symptoms and describe palliative interventions that are unique to advanced pancreatic cancer

GASTRIC/ESOPHAGEAL CANCER

  • Discuss the role of combined modality treatments in the management of patients with localized esophageal EGJ and gastric cancers
  • Discuss the clinical evidence supporting the use of perioperative chemotherapy for gastroesophageal cancers
  • Identify new targeted therapies and their mechanism of action and discuss the clinical evidence supporting the use of targeted therapies the management of advanced esophageal, EGJ and gastric
Additional information
Supporters: 

This activity is supported by an educational donation provided by:

  • Amgen

This activity is supported by educational grants from:

  • Bayer HealthCare Pharmaceuticals Inc.
  • Lilly USA, LLC
  • Pfizer
Course summary
Available credit: 
  • 6.50 Participation
  • 6.50 Nurse
  • 6.50 Pharmacist
  • 6.50 Physician
Course opens: 
11/07/2012
Course expires: 
01/28/2013
Event starts: 
11/07/2012 - 8:00am
Event ends: 
11/07/2012 - 5:00pm
Cost:
$0.00
Searle Center
Seeley G. Mudd Building (Duke Univ)
10 Searle Center Drive
Durham, NC 27710
United States

Available Credit

  • 6.50 Participation
  • 6.50 Nurse
  • 6.50 Pharmacist
  • 6.50 Physician

Accreditation Period

Course opens: 
11/07/2012
Course expires: 
01/28/2013

Price

Cost:
$0.00
Please login or register to take this course.